GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript

GSK Pharma's Q1 FY26 earnings call revealed flat revenue growth (0%) due to softer-than-expected tailwinds in antibiotics and dermatology, compounded by a ~1.7% supply hit from a fire incident at one of its CMOs (largely impacting Calpol). Despite the muted topline, EBITDA margin expanded 290 basis points to 31.2% with 9.3% growth, PAT rose 12.7%, and EPS was Rs 12.08 (up 13%), with 100% cash conversion. The company is re-entering oncology after a decade, launching Zejula (ovarian cancer, TAM ~5,000 patients) and Jemperli (endometrial cancer, TAM ~700-1,000 patients) starting August 2025. Shingrix continues strong traction at 9,000-10,000 doses/month with an FY26 target of 100,000+ doses (~Rs 100 cr). Management reaffirmed commitment to double-digit FY26 revenue growth and expects margins to be sustained over the next 2-3 years despite lower-margin innovative products entering the mix.